Clinical trials: Bone Marrow
Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.
- Trial name
- EWOG MDS 2006 (NCT00662090)
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- University Hospital Freiburg
Systemic Sclerosis
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
This is a Phase I, single arm, open label, single center pilot study to assess a reduced-intensity conditioning regimen, bone marrow transplantation with high dose cyclophosphamide (PTCy) in recipients with refractory systemic…
- Trial name
- NCT05298358
- Testing
- RIC alloBMT w PTCy in refractory SSc
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research
The purpose of this study is to collect a blood or bone marrow sample from patients with multiple myeloma and from volunteers without myeloma.
- Trial name
- NCT01382615
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: SL-401 Azacitidine Venetoclax
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT03113643
- Testing
- Azacitidine, SL-401, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Myelofibrosis
Ruxolitinib in Patients With Myelofibrosis
Prospective study to evaluate the response of myelofibrosis patients to ruxolitinib and it's adverse events on patients (1 year observational study).
- Trial name
- NCT05762874
- Testing
- Ruxolitinib
- Volunteers
- 51 people
- Sponsor
- Assiut University
JAK2 Mutation
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm.
- Trial name
- NCT07249840
- Testing
- Ropeginterferon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Polycythemia Vera (PV)
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon.
- Trial name
- NCT07232290
- Testing
- Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Immunocompromised, Bone Marrow Transplant
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
The purpose of this research study is to examine the pharmacokinetics (the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body) of micafungin when it is given at 5mg/kg dose to…
- Conditions
- Immunocompromised, Bone Marrow Transplant, Cancer
- Trial name
- Micafungin (NCT02057289)
- Testing
- Micafungin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Myelodysplastic Syndrome
Erlotinib in Higher Risk Myelodysplastic Syndrome
The aim of this study is to evaluate the toxicity and therapeutic efficacy of erlotinib in high-risk myelodysplastic syndrome (MDS) patients (with at least 10% of bone marrow blasts) ineligible for or having failed intensive…
- Trial name
- NCT01085838
- Testing
- Erlotinib
- Where
- 14 sites in France
- Volunteers
- 30 people
- Sponsor
- Groupe Francophone des Myelodysplasies
CML (Chronic Myelogenous Leukemia)
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Bone Marrow Edema, Knee Osteoarthritis
Focused Extracorporeal Shockwave Therapy for Knee Arthritis
Subchondral bone marrow lesions (BMLs) in knee osteoarthritis (OA) are strongly associated with presence and severity of knee pain, structural deterioration, disease progression with an increased risk of total knee arthroplasty.
- Conditions
- Bone Marrow Edema, Knee Osteoarthritis, Knee Pain Chronic
- Trial name
- NCT05596591
- Testing
- Focused extracorporeal shockwave therapy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kessler Foundation
Chronic Myeloid Leukemia
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
In this study, the efficacy of nilotinib at 400 mg BID will be compared with imatinib at 400 mg BID in suboptimal molecular response patients.
- Trial name
- RE-NICE (NCT01400074)
- Testing
- Nilotinib, Imatinib
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul St. Mary's Hospital
Polycythemia Vera
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236…
- Trial name
- PreVail (NCT07859423)
- Testing
- AG-236
- Volunteers
- 245 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Fanconi Anemia
Eltrombopag for Fanconi Anemia
Background: Fanconi anemia is a genetic disease. Some people with it have reduced blood cell counts. This means their bone marrow no longer works properly.
- Trial name
- NCT03206086
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Biliary Tract Neoplasms, Pancreatic Neoplasms
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
- Trial name
- NCT07160283
- Testing
- Bile duct cancer cohort, Pancreatic cancer cohort
- Volunteers
- 96 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Respiratory Distress Syndrome, Adult
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- START (NCT02097641)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Michael A. Matthay
Cardiomyopathy, Dilated
Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy
The purpose of this study is to determine whether an autologous stem cell infusion through catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy. Process: 1.
- Trial name
- NCT01504594
- Testing
- Intracoronary autologous stem cell infusion
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Fungal Infection, Bacterial Infection
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
The safety and tolerability of hLF 1-11 given in multiple doses has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal or…
- Trial name
- NCT00430469
- Testing
- human lactoferrin (hLF1-11)
- Where
- Netherlands
- Sponsor
- AM-Pharma
Osteochondral Lesion of Talus
Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success?
Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may…
- Trial name
- OUTBACK (NCT04475341)
- Testing
- BMS + Bone Marrow Aspirate Concentrate, BMS alone
- Volunteers
- 96 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.